bal101553
Small moleculeexperimental
Clinical trial activity
4 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Jun 1, 2011 (NCT01397929)
Timeline
2010s
- Jan 1, 2011
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- TubulinINHIBITOR
Tubulin inhibitor
- Tubulin beta-4B chain (TUBB4B) ↗
- Tubulin beta-1 chain (TUBB1) ↗
- Tubulin alpha-3C chain (TUBA3C) ↗
- Tubulin alpha-4A chain (TUBA4A) ↗
- Tubulin beta-3 chain (TUBB3) ↗
- Tubulin alpha-1A chain (TUBA1A) ↗
- Tubulin beta-4A chain (TUBB4A) ↗
- Tubulin beta-8 chain (TUBB8) ↗
- Tubulin beta chain (TUBB) ↗
- Tubulin alpha-1B chain (TUBA1B) ↗
- Tubulin alpha-1C chain (TUBA1C) ↗
- Tubulin alpha-3E chain (TUBA3E) ↗
- Tubulin beta-2A chain (TUBB2A) ↗
- Tubulin beta-2B chain (TUBB2B) ↗
- Tubulin beta-6 chain (TUBB6) ↗
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- bal101553
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03250299 | Phase 1 | Jun 7, 2017 | Basilea Pharmaceutica, Johns Hopkins University, National Cancer Institute (NCI) |
| NCT02895360 | Phase 1/Phase 2 (Phase 2) | Aug 1, 2016 | Basilea Pharmaceutica |
| NCT02490800 | Phase 1/Phase 2 (Phase 2) | Jun 1, 2015 | Basilea Pharmaceutica |
| NCT01397929 | Phase 1/Phase 2 (Phase 2) | Jun 1, 2011 | Basilea Pharmaceutica |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Basilea Pharmaceutica | For profit | 4 | 4 | 2 | 2011 |
| Johns Hopkins University | Academic/Hospital | 1 | 0 | 1 | 2017 |
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 2017 |
3 organizations
Page 1 / 1